Long-term follow-up results and complications in cancer patients with persistent nephrostomy due to malignant ureteral obstruction.
Dislodgement
Malignant ureteral obstruction
Percutaneous nephrostomy
Pyelonephritis
Journal
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
ISSN: 1433-7339
Titre abrégé: Support Care Cancer
Pays: Germany
ID NLM: 9302957
Informations de publication
Date de publication:
Nov 2020
Nov 2020
Historique:
received:
30
12
2019
accepted:
30
07
2020
pubmed:
7
8
2020
medline:
15
12
2020
entrez:
7
8
2020
Statut:
ppublish
Résumé
We aimed to evaluate the long-term complications and predisposing factors for these complications in patients with malignant ureteral obstruction (MUO) treated with percutaneous nephrostomy (PN). The records of patients with MUO treated with PN between January 2015 and 2018 were retrospectively reviewed for PN dislodgement, PN obstruction, PN replacement, pyelonephritis, hospitalizations due to PN complications, and other complications due to PN such as macroscopic hematuria, skin infections, or renal/perirenal abscess. Data for a total of 147 patients (229 renal units [RU], 107 males, 40 females) were evaluated. In 174 (76%) RU, PN was replaced due to PN dislodgement. The predisposing factors for PN dislodgement were follow-up time, body mass index (BMI), chemotherapy, diabetes mellitus (DM), low educational level (LEL), pyelonephritis, and catheter-related skin infections (CSRI). The PN was replaced in 40 RU due to obstruction. The predisposing factors for obstruction were follow-up time and BMI. Pyelonephritis developed at least once in 61 (41.5%) patients. Follow-up time, BMI, previous surgery, DM, and LEL were the predisposing factors for pyelonephritis. CSRI developed in 16 RU. Follow-up time, BMI, DM, and LEL were the predisposing factors for CSRI. Macroscopic hematuria developed in 11 patients. Follow-up time, previous surgery, DM, chemotherapy, and LEL were predisposing factors for macroscopic hematuria. The most common complication in patients with MUO treated with PN was PN dislodgement. However, life-threatening complications such as macroscopic hematuria and severe infections can also occur. Patients with DM, LEL, and chemotherapy are at high risk of PN-related complications.
Identifiants
pubmed: 32757161
doi: 10.1007/s00520-020-05662-z
pii: 10.1007/s00520-020-05662-z
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
5581-5588Références
Barton DP, Morse SS, Fiorica JV, Hoffman MS, Roberts WS, Cavanagh D (1992) Percutaneous nephrostomy and ureteral stenting in gynecologic malignancies. Obstet Gynecol 80:805–811
pubmed: 1407920
Plesinac-Karapandzic V, Masulovic D, Markovic B, Djuric-Stefanovic A, Plesinac S, Vucicevic D, Milovanovic Z, Milosevic Z (2010) Percutaneous nephrostomy in the management of advanced and terminal-stage gynecologic malignancies: outcome and complications. Eur J Gynaecol Oncol 31:645–650
pubmed: 21319508
Kanou T, Fujiyama C, Nishimura K, Tokuda Y, Uozumi J, Masaki Z (2007) Management of extrinsic malignant ureteral obstruction with urinary diversion. Int J Urol 14:689–692. https://doi.org/10.1111/j.1442-2042.2007.01747.x
doi: 10.1111/j.1442-2042.2007.01747.x
pubmed: 17681056
Ganatra AM, Loughlin KR (2005) The management of malignant ureteral obstruction treated with ureteral stents. J Urol 174:2125–2128. https://doi.org/10.1097/01.ju.0000181807.56114.b7
doi: 10.1097/01.ju.0000181807.56114.b7
pubmed: 16280741
Lienert A, Ing A, Mark S (2009) Prognostic factors in malignant ureteric obstruction. BJU Int 104:938–941. https://doi.org/10.1111/j.1464-410X.2009.08492.x
doi: 10.1111/j.1464-410X.2009.08492.x
pubmed: 19338533
Russo P (2000) Urologic emergencies in the cancer patient. Semin Oncol 27:284–298
pubmed: 10864217
Chung SY, Stein RJ, Landsittel D, Davies BJ, Cuellar DC, Hrebinko RL, Tarin T, Averch TD (2004) 15-year experience with the management of extrinsic ureteral obstruction with indwelling ureteral stents. J Urol 172:592–595. https://doi.org/10.1097/01.ju.0000130510.28768.f5
doi: 10.1097/01.ju.0000130510.28768.f5
pubmed: 15247739
Yossepowitch O, Lifshitz DA, Dekel Y, Gross M, Keidar DM, Neuman M, Livne PM, Baniel J (2001) Predicting the success of retrograde stenting for managing ureteral obstruction. J Urol 166:1746–1749
doi: 10.1016/S0022-5347(05)65666-2
Wah TM, Weston MJ, Irving HC (2004) Percutaneous nephrostomy insertion: outcome data from a prospective multi-operator study at a UK training Centre. Clin Radiol 59:255–261. https://doi.org/10.1016/j.crad.2003.10.021
doi: 10.1016/j.crad.2003.10.021
pubmed: 15037138
McDevitt JL, Acosta-Torres S, Zhang N, Hu T, Odu A, Wang J, Xi Y, Lamus D, Miller DS, Pillai AK (2017) Long-term percutaneous nephrostomy management of malignant urinary obstruction: estimation of optimal exchange frequency and estimation of the financial impact of patient compliance. J Vasc Interv Radiol 28:1036–1042. https://doi.org/10.1016/j.jvir.2017.02.031
doi: 10.1016/j.jvir.2017.02.031
pubmed: 28385361
Ching KC, Shlansky-Goldberg RD, Trerotola SO (2017) A durable percutaneous U-tube nephrostomy for management of a recurrently displaced locking loop catheter. J Vasc Interv Radiol 28:475–477. https://doi.org/10.1016/j.jvir.2016.10.025
doi: 10.1016/j.jvir.2016.10.025
pubmed: 28231929
Misra S, Coker C, Richenberg J (2013) Percutaneous nephrostomy for ureteric obstruction due to advanced pelvic malignancy: have we got the balance right? Int Urol Nephrol 45:627–632. https://doi.org/10.1007/s11255-013-0458-3
doi: 10.1007/s11255-013-0458-3
pubmed: 23666587
Szvalb AD, El Haddad H, Rolston KV, Sabir SH, Jiang Y, Raad II, Viola GM (2019) Risk factors for recurrent percutaneous nephrostomy catheter-related infections. Infection. 47:239–245. https://doi.org/10.1007/s15010-018-1245-y
doi: 10.1007/s15010-018-1245-y
pubmed: 30406481
Cronan JJ, Horn DL, Marcello A, Robinson A, Paolella LP, Lambiase RE, Haas RA, Opal S, Dorfman GS (1989) Antibiotics and nephrostomy tube care: preliminary observations Part II. Bacteremia Radiology 172:1043–1045. https://doi.org/10.1148/172.3.1043
doi: 10.1148/172.3.1043
pubmed: 2772208
Bahu R, Chaftari AM, Hachem RY, Ahrar K, Shomali W, El Zakhem A, Jiang Y, AlShuaibi M, Raad II (2013) Nephrostomy tube related pyelonephritis in patients with cancer: epidemiology, infection rate and risk factors. J Urol 189:130–135. https://doi.org/10.1016/j.juro.2012.08.094
doi: 10.1016/j.juro.2012.08.094
pubmed: 23164390
Degirmenci T, Gunlusoy B, Kozacioglu Z, Arslan M, Ceylan Y, Ors B, Minareci S (2013) Utilization of a modified Clavien classification system in reporting complications after ultrasound-guided percutaneous nephrostomy tube placement: comparison to standard Society of Interventional Radiology practice guidelines. Urology. 81:1161–1167. https://doi.org/10.1016/j.urology.2013.02.038
doi: 10.1016/j.urology.2013.02.038
pubmed: 23618426
Lunglmayr G, Pecherstorfer M (1969) Long-term drainage of the kidney by U-tube pyelonephrostomy. Br J Urol 41:394–396. https://doi.org/10.1111/j.1464-410x.1969.tb09937.x
doi: 10.1111/j.1464-410x.1969.tb09937.x
pubmed: 5808724
Binder C, Gonick P, Ciavarra V (1971) Experience with silastic U-tube nephrostomy. J Urol 106:499–502. https://doi.org/10.1016/s0022-5347(17)61326-0
doi: 10.1016/s0022-5347(17)61326-0
pubmed: 5000898
Noureldin YA, Diab C, Valenti D, Andonian S (2016) Circle nephrostomy tube revisited. Can Urol Assoc J 10:E223–E228. https://doi.org/10.5489/cuaj.3596
doi: 10.5489/cuaj.3596
pubmed: 28255412
pmcid: 5325750
Kohler JP, Lyon ES, Schoenberg HW (1980) Reassessment of circle tube nephrostomy in advanced pelvic malignancy. J Urol 123:17–18. https://doi.org/10.1016/s0022-5347(17)55753-5
doi: 10.1016/s0022-5347(17)55753-5
pubmed: 7351714
El Tayeb MM, Borofsky MS, Lingeman JE (2017) The circle nephrostomy tube: an attractive nephrostomy drainage system following complex percutaneous Nephrolithotomy. Urology 103:251–255. https://doi.org/10.1016/j.urology.2017.01.012
doi: 10.1016/j.urology.2017.01.012
pubmed: 28108324
pmcid: 5870131
De Nunzio C, Cicione A, Izquierdo L et al (2019) Multicenter analysis of postoperative complications in octogenarians after radical cystectomy and ureterocutaneostomy: the role of the frailty index. Clin Genitourin Cancer 17:402–407. https://doi.org/10.1016/j.clgc.2019.07.002
doi: 10.1016/j.clgc.2019.07.002
pubmed: 31402279